Purpose

This needs assessment survey, developed with input from an expert Scientific Steering Committee, including Dr. Michael Chu, Dr. Robert Puckrin, and Dr. Sita Bhella, aims to gather insights on the use of CAR T cell therapies in DLBCL, focusing on awareness, barriers to implementation, and strategies to manage treatment-related adverse events. The survey is anonymous, and your responses will remain confidential. Thank you for your time and willingness to share your expertise.

*The first 60 participants who complete the survey will be eligible to receive $150 for their time commitment and contributions.

T